Lupus & antiphospholipid syndrome
Diving deep into lupus: Gastrointestinal involvement insights from the Oman lupus study
Authors' conclusion
A higher mortality rate was found to be associated with organ involvement, disease duration, autoantibody profile, and specific complications.
Study context
- Population
- Patients meeting classification criteria for systemic lupus erythematosus (SLE), Oman Lupus Study, January 2006 to February 202091 with gastrointestinal (GI) manifestations
- Participants
- 1,160 patients
- Exposure
- Paediatric vs adult SLE patients; patients with vs without GI involvement
- Outcome
- Prevalence of GI manifestations in lupus patients
Methodological detailspart of the Oman Lupus Study
- Part of the Oman Lupus Study
Main finding
As reported in the abstract
Prevalence of GI manifestations
P = 0.755
Observational data: associations, not effects.
Further findings
Factors associated with ischemic colitis
- Longer disease duration
- P < 0.001
- B2-glycoprotein I (B2GPI) autoantibody positivity
- P < 0.0001
- Hematologic manifestations
- P = 0.001
- LN
- P = 0.007
- Pulmonary complications
- P = 0.000-.039
- Some cardiac complications
- P = 0.012-.269
Mortality in patients with GI involvement
- Mortality rate with GI involvement (greater)
- 24.37%
- Ischemic colitis
- P = 0.005
- Chronic peritonitis
- P < 0.001
- Spleen/liver infarction
- P = 0.001
- Sepsis, thrombocytopenia and internal organ involvement rates significantly associated with increased mortality
Original publication
Diving deep into lupus: Gastrointestinal involvement insights from the Oman lupus study. Lupus. Published 14 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →